Oculis’ Phase 3 program for diabetic macular edema did not meet endpoints, prompting the company to shift pipeline priorities. The setback delays the prospect of a topical eye-drop option for DME and redirects development focus toward other late-stage candidates targeting optic neuropathies and dry eye disease. The company’s stock reaction reflected the market impact of missing a pivotal milestone, and the pivot indicates a rapid reallocation of clinical and regulatory resources. For ophthalmology developers and investors, the key takeaway is how quickly pipeline decisions follow Phase 3 readouts—especially in specialty segments where successful launches depend on tight endpoint definitions. Next steps for Oculis will likely center on demonstrating differentiating efficacy profiles in the programs now prioritized, including trial readouts that can stabilize investor expectations.